HST Global, Inc. Encouraged by FDA Approval of Dendreon’s Provenge

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc., (OTCBB:HSTC) today was encouraged by news of the FDA approval of Dendreon Corp’s (NASDAQ: DNDN) Provenge drug for prostate cancer. Provenge is aimed at certain men with advanced prostate cancer and uses a man’s own immune system to fight the disease.

“The FDA approval of Provenge is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees.”

Dr. Mitchell Gold, CEO and President of Dendreon stated "The FDA approval of Provenge is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees."

Ron Howell, President and CEO stated “We congratulate Dendreon Corp on receiving the approval from the FDA, as this is a testament to the perseverance and dedication of their entire corporate team. We are encouraged by the FDA’s action in approving Provenge. HST is committed to the acquisition and development of Health and Wellness Centers offering proven alternative and immunotherapy drug candidates that have shown high efficacy in the treatment of various cancers.”

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.